Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: Lessons from an 8-year follow-up study of 599 patients

Diabetes Research and Clinical Practice

Volumn 49, Issue 2-3, 2000, Pages 187-194

  Rachmani, Rita ^a   Levi, Zohar ^a   Lidar, Merav ^a   Slavachevski, Inna ^a   Half Onn, Elizabeth ^a   Ravid, Mordchai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Diabetes mellitus type 2; Microalbuminuria; Screening

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MICROALBUMINURIA; REFERENCE VALUE; SCREENING TEST; URINALYSIS;

ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME FACTORS;

EID: 0033839287     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00155-8     Document Type: Article

References (37)

1. Mogensen C.E. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 42:1999;263-285.
2. Yudkin J.S., Forrest R.D., Jackson C.A. Microalbuminuria is a predictor of vascular disease in non-diabetic subjects. Lancet. 2:1988;530-533.
3. Parving H.H. Renoprotection in diabetes:genetic and non-genetic risk factors and treatment. Diabetologia. 41:1998;745-759.
4. Agewall S., Wikstrand J., Ljungman S., Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk factor intervention study group. Am. J. Cardiol. 80(2):1997;164-169.
5. Maattock M.B., Barnes D.J., Viberti G., Keen H., Burt D., Hughes J.M., Fitzgerald A.P., Sandhu B., Jackson P.G. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes. 47:1998;1786-1792.
6. Gall A.M., Haugaard P., Broch-Johnsen K., Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin-dependent diabetes mellitus: prospective observational study. Br. Med. J. 314:1997;783-788.
7. Hutchison A.S., O'Reilly D. St. J., MacCuish A.C. Albumin excretion rates, albumin concentration and albumin: creatinine ration compared for screening diabetics for slight albuminuria. Clin. Chem. 34:1988;2019-2021.
8. H.M.J. Krans, M. Porta, H. Keen, Diabetes care and research in Europe: The St. Vincent Declaration Action Program, World Health Organization, Copenhagen 1992, pp 29-32.
9. Powrie J.K., Watts G.F., Ingham J.N., Taub N.N., Talmud P.J., Shaw K.M. Role of glycemic control in development of microalbuminuria in patients with insulin dependent diabetes. Br. Med. J. 309:1994;1608-1612.
10. Schmitz A., Vith M., Mogensen C.E. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia. 37:1994;1251-1258.
11. Damsgaard E.M., Froland A., Jorgensen O.D., Mogensen C.E. Microalbuminuria as a predictor of increased mortality in elderly people. Br. Med. J. 300:1990;297-300.
12. Mathiesen E.R., Hommel E., Giese J., Parving H.H. Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br. Med. J. 303:1991;81-87.
13. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 317:1998;703-713.
14. Ravid M., Brosh D., Ravid-Safran D., Levy Z., Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch. Int. Med. 158:1998;998-1004.
15. Bartels H., Bohmer M., Heierl C. Serum creatinine determination without protein precipitation. Clin. Chim. Acta. 37:1972;193-197.
16. Allain C.C., Poon L.S., Chan C.S.G., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 10:1974;470-475.
17. Badham D., Trinder P. An improved color reagent for the determination of blood glucose by the oxidase system. Analyst. 97:1972;142-145.
18. Sathianatan P., Rege V.P., Barron J.L. Immunoturbidimetric determination of urinary albumin with a centrifugal analyzer. Clin. Chem. 32:1986;202.
19. Levy A.S., Bosch J.P., Breyer Lewis J., Green T., Togers N., Toth D. A more accurate methods to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Int. Med. 130:1999;4461-4470.
20. SAS/STAT Software, 1990. Calis and Logistic Procedures, Release 6.04. Cary NC: SAS Institute Inc.
21. Ulm K. A statistical method for assessing a threshold in epidemiological studies. Stat. Med. 10:1991;341-349.
22. Jones R.H., Molitoris B.A. A statistical method for determining the breakpoint of two lines. Anal. Biochem. 141:1984;287-290.
23. Osterby R. Lessons from kidney biopsies. Diabetes Metabol. Rev. 12:1996;151-174.
24. Berg U.B., Torbjornsdotter T.B., Jarenko G., Thalme B. Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia. 41:1998;1047-1056.
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329:1993;977-986.
26. Okhubo Y., Kishikawa H., Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized, prospective 6-year study. Diabetes Res. Clin. Pract. 28:1995;103-117.
27. M. Ravid, D. Brosh, Z. Levi, Y. Bar-Dayan, D. Ravid, R. Rachmani, Use of enalapril to attenuate decline in renal function in normotensive patients with type 2 diabetes mellitus. A randomized controlled trial, Ann. Int. Med. 1998;982-988.
28. Ravid M., Neuman L., Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type 2: effect of ACE inhibitors. Kidney Int. 47:1995;907-910.
29. Hay J.W., Hu W.M., Ashrof T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 15:1999;47-74.
30. Pyorala K., Pedersen T.R., Kjekshus J., Foergeman O., Olsson A.G., Thorglirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care. 20:1997;614-620.
31. The sixth report of the Joint Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch. Int. Med. 157:1997;2413-2446.
32. Golan L., Birkmeyer J., Gibbert Welch H. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Int. Med. 131:1999;600-667.
33. Mackenzie H.S., Brenner B.M. Current strategies for retarding progression of renal disease. Am. J. Kidney Dis. 31:1998;161-170.
34. Berrut G., Bouhanick B., Fabbri P., Guillotean G., Blied F., Le Jenune J.J., Fressinaud P., Marre M. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin. Nephrol. 48:1997;92-97.
35. Dinneen S.F., Gerstein H.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch. Int. Med. 157:1997;1413-1418.
36. Schmitz A. Microalbuminuria, blood pressure, metabolic control and renal involvement: longitudinal studies in white, non-insulin-dependent diabetic patients. Am. J. Hypertens. 10:1997;189S-197.
37. Ravid M., Savin H., Jutrin J., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann. Int. Med. 118:1993;577-581.